-
Mashup Score: 5CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) - 5 month(s) ago
UroToday’s exclusive Video Lecture coverage of CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?).
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65When is prostate cancer really cancer? - 5 month(s) ago
Abstract. Prostate cancer (PC) is a major cause of cancer-related deaths worldwide, with far more diagnoses than deaths annually. Recent discussions have c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Dr. Max Bowman - 6 month(s) ago
Max Bowman, MD, is a urologist caring for patients at UCSF Health. Learn more about Dr. Bowman’s specialties and training.
Source: www.ucsfhealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Medical Student Who Can’t Stop Winning Gold Medals - 7 month(s) ago
Lee Kiefer is the most successful fencer in U.S. history. When will she trade her sword for a stethoscope?
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay - 9 month(s) ago
Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland…
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay - 9 month(s) ago
Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland…
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Opinion | Blaming Israel for Rescuing Its People - 9 month(s) ago
Hamas hid four hostages in a crowded civilian area and fired on rescuers.
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1San Francisco’s Train System Still Uses Floppy Disks—and Will for Years - 11 month(s) ago
Three 5.25-inch floppy disks help keep Muni running every morning. A tech upgrade could take until 2030.
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37
Matthew Cooperberg introduces the inaugural patient-oriented journal club for patients diagnosed with prostate cancer. This patient journal club aims to highlight prostate cancer research, selected trials, and pivot to open discussion between expert clinicians and patients. The 15-year update from the ProtecT trial, led by Professors Freddie Hamdy and Jenny Donovan is the selected trial for this…
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer | NEJM - 11 month(s) ago
Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzaluta…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
And thanks to @urotoday, you can watch both the talks and discussion sessions here: https://t.co/A5E2FThgBh